What is Supernus Pharmaceuticals, Inc.'s earnings per share (EPS)?

Supernus Pharmaceuticals, Inc. (SUPN) reported diluted earnings per share of -$0.68 for fiscal year 2025. This represents a -151.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Supernus Pharmaceuticals, Inc. (SUPN) Financials

SUPN

Trailing 12 months to June 30, 2026

Revenue $830.4M +24.9% YoY

Net Income -$109.9M -270.4% YoY

EPS (Diluted) -$1.92 -267.0% YoY

Free Cash Flow $18.8M -89.9% YoY

Market Cap $2.5B as of Oct 10, 2026

Price / Sales 3.0x on $830.4M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 2.4x on $1.0B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SUPN SEC filings page.

Supernus Pharmaceuticals, Inc. (SUPN) reported $830.4M in revenue over the twelve months to Jun 30, 2026, up 24.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SUPN FY2025 2026-10-03

Revenue and gross margin expanded, but a sharp selling-cost surge turned an otherwise cash-generating business unprofitable in FY2025.

The FY2025 setback is expense-driven rather than gross-economics-driven: revenue reached $719M while gross margin rose to 89.6%, so deterioration occurred below production costs. SG&A rose from $322M to $486M, overwhelming gross profit and pushing the operating result into a loss.

Cash conversion weakened alongside earnings: operating cash flow fell from $172M to $47M. Free cash flow likewise fell from $171M to $46M, showing the FY2025 earnings reversal reached cash rather than remaining an accounting-only event.

The balance sheet remains lightly debt-funded, with debt-to-equity at 0.4 and current ratio at 1.9. Yet current assets fell to $644M while receivables and inventory increased, pointing to working capital absorbing liquidity even as capital expenditures were only $1.3M.

Financial Health Signals

Financial Health Score 53/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Supernus Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Supernus Pharmaceuticals, Inc. has an operating margin of -8.7%, meaning the company loses $9 on every $100 of revenue. This results in a profitability score of 29/100. This is down from 12.3% the prior year.

Growth

Supernus Pharmaceuticals, Inc.'s revenue grew 8.6% year-over-year to $719.0M, a solid pace of expansion. This earns a growth score of 62/100.

Leverage

Supernus Pharmaceuticals, Inc. carries a low D/E ratio of 0.37, meaning only $0.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Supernus Pharmaceuticals, Inc.'s current ratio of 1.90 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Supernus Pharmaceuticals, Inc. converts 6.4% of revenue into free cash flow ($46.0M). This strong cash generation earns a score of 77/100.

Returns

Supernus Pharmaceuticals, Inc. posts a -3.6% return on equity (ROE), meaning it loses $4 for every $100 of shareholders' equity. This results in a returns score of 27/100. This is down from 7.1% the prior year.

Altman Z-Score Safe

4.92

Supernus Pharmaceuticals, Inc. scores 4.92, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.5B) relative to total liabilities ($390.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Supernus Pharmaceuticals, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Supernus Pharmaceuticals, Inc. reported a net loss of $38.6M while generating $47.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$219.1M

YoY+32.4%

QoQ+5.5%

5Y CAGR+9.2%

10Y CAGR+15.5%

Supernus Pharmaceuticals, Inc. generated $219.1M in revenue in Q2 2026. This represents an increase of 32.4% from the same quarter a year earlier. Against the prior quarter it is up 5.5%.

EBITDA

-$57.6M

YoY-555.4%

QoQ-423.4%

Supernus Pharmaceuticals, Inc.'s EBITDA was -$57.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 555.4% from the same quarter a year earlier. Against the prior quarter it is down 423.4%.

Net Income

-$58.4M

YoY-359.4%

QoQ-2445.6%

Supernus Pharmaceuticals, Inc. reported -$58.4M in net income in Q2 2026. This represents a decrease of 359.4% from the same quarter a year earlier. Against the prior quarter it is down 2445.6%.

EPS (Diluted)

-$1.01

YoY-352.5%

QoQ-2425.0%

Supernus Pharmaceuticals, Inc. earned -$1.01 per diluted share (EPS) in Q2 2026. This represents a decrease of 352.5% from the same quarter a year earlier. Against the prior quarter it is down 2425.0%.

Cash & Balance Sheet

Free Cash Flow

-$5.4M

YoY-109.3%

QoQ-108.1%

Supernus Pharmaceuticals, Inc. recorded an outflow of $5.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 109.3% from the same quarter a year earlier. Against the prior quarter it is down 108.1%.

Cash & Debt

$180.0M

YoY+24.4%

QoQ-2.7%

5Y CAGR-4.3%

10Y CAGR+17.4%

Supernus Pharmaceuticals, Inc. held $180.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

58M

YoY+3.7%

QoQ+0.2%

5Y CAGR+1.8%

10Y CAGR+1.6%

Supernus Pharmaceuticals, Inc. had 58M shares outstanding in Q2 2026. This represents an increase of 3.7% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

84.6%

YoY-5.2pp

QoQ-4.1pp

5Y change+2.3pp

Supernus Pharmaceuticals, Inc.'s gross margin was 84.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.1 percentage points.

Operating Margin

-26.5%

YoY-33.8pp

QoQ-22.4pp

5Y change-50.6pp

10Y change-49.0pp

Supernus Pharmaceuticals, Inc.'s operating margin was -26.5% in Q2 2026, reflecting core business profitability. This is down 33.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 22.4 percentage points.

Net Margin

-26.7%

YoY-40.3pp

QoQ-25.6pp

5Y change-43.4pp

10Y change-46.5pp

Supernus Pharmaceuticals, Inc.'s net profit margin was -26.7% in Q2 2026, showing the share of revenue converted to profit. This is down 40.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 25.6 percentage points.

Return on Equity

-5.7%

YoY-7.8pp

QoQ-5.5pp

5Y change-8.7pp

10Y change-15.0pp

Supernus Pharmaceuticals, Inc.'s ROE was -5.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 7.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.5 percentage points.

Capital Allocation

R&D Spending

$29.5M

YoY+33.2%

QoQ-25.3%

5Y CAGR+13.8%

Supernus Pharmaceuticals, Inc. invested $29.5M in research and development in Q2 2026. This represents an increase of 33.2% from the same quarter a year earlier. Against the prior quarter it is down 25.3%.

Capital Expenditures

$568K

YoY+24.8%

Supernus Pharmaceuticals, Inc. invested $568K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 24.8% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

SUPN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SUPN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$830.4M	$719.0M+8.6%	$661.8M+8.9%	$607.5M-8.9%	$667.2M+15.1%	$579.8M+11.4%	$520.4M+32.5%	$392.8M-3.9%	$408.9M+35.3%	$302.2M+40.6%	$215.0M+45.8%	$147.5M+59.1%	$92.7M+671.1%	$12.0M+712.1%	$1.5M+84.3%	$803K
Cost of Revenue	$99.0M	$74.6M-4.3%	$77.9M-7.0%	$83.8M-3.9%	$87.2M+16.2%	$75.1M+43.1%	$52.5M+214.9%	$16.7M+8.5%	$15.4M+0.9%	$15.2M+26.9%	$12.0M+42.3%	$8.4M+46.3%	$5.8M+421.6%	$1.1M	N/A	N/A
Gross Profit	$731.4M	$644.4M+10.4%	$583.9M+11.5%	$523.7M-9.7%	$580.0M+14.9%	$504.7M+7.9%	$467.9M+24.4%	$376.1M-4.4%	$393.5M+37.1%	$287.0M+41.4%	$203.0M+46.0%	$139.0M+60.0%	$86.9M+696.3%	$10.9M	N/A	N/A
R&D Expenses	$126.1M	$106.2M-2.4%	$108.8M+18.8%	$91.6M+22.9%	$74.6M-17.6%	$90.5M+19.1%	$76.0M+9.9%	$69.1M-22.5%	$89.2M+79.9%	$49.6M+15.9%	$42.8M+46.9%	$29.1M+48.8%	$19.6M+13.6%	$17.2M-26.7%	$23.5M-23.2%	$30.6M
SG&A Expenses	$560.9M	$485.6M+51.0%	$321.6M-4.4%	$336.4M-10.8%	$377.2M+23.8%	$304.8M+51.9%	$200.7M+31.0%	$153.2M-0.9%	$154.7M+12.2%	$137.9M+30.1%	$106.0M+19.0%	$89.1M+22.7%	$72.6M+30.6%	$55.6M+176.1%	$20.1M+153.9%	$7.9M
Operating Income	-$130.5M	-$62.3M-176.3%	$81.7M+1649.9%	-$5.3M-111.4%	$46.1M-46.4%	$86.0M-50.5%	$173.7M+16.9%	$148.6M+2.9%	$144.4M+45.1%	$99.5M+83.6%	$54.2M+160.1%	$20.8M+494.9%	-$5.3M+91.5%	-$61.9M-46.8%	-$42.2M-11.7%	-$37.8M
EBITDA	N/A	$29.3M-81.9%	$162.1M+103.6%	$79.6M-39.6%	$131.7M+11.0%	$118.6M-38.2%	$191.8M+23.6%	$155.2M+2.5%	$151.5M+40.7%	$107.7M+90.2%	$56.6M+160.1%	$21.8M+600.3%	-$4.3M+92.9%	-$61.2M-48.1%	-$41.3M-12.0%	-$36.9M
Interest Expense	N/A	$0	$0-100.0%	$1.3M-48.0%	$2.5M-87.1%	$19.7M+1.3%	$19.4M+6.7%	$18.2M+31.6%	$13.8M+10228.4%	$134K-75.3%	$543K-55.8%	$1.2M-75.2%	$5.0M-36.8%	$7.8M+119.6%	$3.6M+91.6%	$1.9M
Income Tax	-$13.6M	-$10.5M-143.7%	$24.0M+1552.1%	$1.5M+4440.6%	$32K-99.8%	$19.8M-52.6%	$41.7M+21.1%	$34.4M+18.0%	$29.2M-32.7%	$43.3M+206.1%	-$40.9M-6233.9%	$666K+5.7%	$630K	$0	$0+100.0%	-$16.2M
Net Income	-$109.9M	-$38.6M-152.2%	$73.9M+5584.6%	$1.3M-97.9%	$60.7M+13.7%	$53.4M-57.9%	$127.0M+12.3%	$113.1M+1.9%	$111.0M+93.8%	$57.3M-37.2%	$91.2M+554.2%	$13.9M+227.6%	-$10.9M+88.2%	-$92.3M-99.4%	-$46.3M-186.0%	$53.8M
EPS (Basic)	N/A	-$0.68-150.7%	$1.34+6600.0%	$0.02-98.2%	$1.13+11.9%	$1.01-58.1%	$2.41+11.6%	$2.16+1.4%	$2.13+88.5%	$1.13-38.6%	$1.84+534.5%	$0.29+211.5%	-$0.26+91.0%	-$2.90-6.6%	-$2.72	N/A
EPS (Diluted)	-$1.92	-$0.68-151.5%	$1.32+6500.0%	$0.02-98.1%	$1.04+6.1%	$0.98-58.5%	$2.36+12.4%	$2.10+2.4%	$2.05+89.8%	$1.08-38.6%	$1.76+528.6%	$0.28+207.7%	-$0.26+91.0%	-$2.90	-$2.72	N/A
Diluted Shares (Avg)	N/A	56M+0.9%	56M+0.8%	56M-10.0%	62M+13.5%	54M+1.2%	54M-0.2%	54M-0.5%	54M+1.5%	53M+3.1%	52M+1.1%	51M+21.1%	42M+32.7%	32M	17M	2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$219.1M+32.4%	$207.7M+38.6%	$211.6M+21.5%	$192.1M+9.3%	$165.5M-1.7%	$149.8M+4.3%	$174.2M+6.0%	$175.7M+14.2%
Cost of Revenue	$33.7M+100.1%	$23.4M+48.4%	$23.0M-11.8%	$19.0M+7.9%	$16.8M-6.1%	$15.8M-3.3%	$26.1M+33.0%	$17.6M-10.3%
Gross Profit	$185.4M+24.7%	$184.3M+37.5%	$188.6M+27.4%	$173.1M+9.5%	$148.6M-1.2%	$134.1M+5.3%	$148.1M+2.3%	$158.1M+17.7%
R&D Expenses	$29.5M+33.2%	$39.4M+46.5%	$27.8M-2.9%	$29.4M+1.1%	$22.1M-15.5%	$26.9M+8.0%	$28.6M+22.7%	$29.0M+28.2%
SG&A Expenses	$133.6M+42.8%	$125.2M+39.2%	$122.4M+54.1%	$179.7M+157.6%	$93.6M+8.9%	$89.9M+4.0%	$79.4M-2.3%	$69.8M-15.7%
Operating Income	-$58.0M-577.4%	-$8.3M+18.8%	-$3.9M-118.4%	-$60.2M-247.5%	$12.1M-46.2%	-$10.3M-225.3%	$21.4M+2249.1%	$40.8M+401.9%
EBITDA	-$57.6M-555.4%	$17.8M+75.8%	$66.2M-17.1%	-$59.7M-244.1%	$12.6M-45.4%	$10.1M-42.4%	$79.9M+28.7%	$41.4M+374.3%
Interest Expense	$2.3M	N/A	N/A	N/A	$0	N/A	$0+100.0%	$0
Income Tax	$723K+112.4%	-$3.7M-161.0%	$2.2M-80.2%	-$12.8M-299.1%	-$5.8M-191.3%	$6.0M+4938.7%	$11.1M+6075.1%	$6.4M-75.1%
Net Income	-$58.4M-359.4%	-$2.3M+80.6%	-$4.2M-127.0%	-$45.1M-217.2%	$22.5M+13.0%	-$11.8M-9637.9%	$15.4M+1225.5%	$38.5M+341.0%
EPS (Basic)	-$1.01-352.5%	-$0.04+81.0%	-$0.07-125.0%	-$0.80-214.3%	$0.40+11.1%	-$0.21	$0.28+1300.0%	$0.70+341.4%
EPS (Diluted)	-$1.01-352.5%	-$0.04+81.0%	-$0.07-125.9%	-$0.80-215.9%	$0.40+11.1%	-$0.21	$0.27+1250.0%	$0.69+337.9%
Diluted Shares (Avg)	58M+2.5%	58M+3.2%	N/A	57M+1.0%	57M+1.6%	56M+0.4%	N/A	56M+2.6%

SUPN Balance Sheet

SUPN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.5B+6.2%	$1.4B+7.1%	$1.3B-25.0%	$1.7B+0.8%	$1.7B+12.3%	$1.5B+29.6%	$1.2B+18.7%	$977.8M+130.4%	$424.5M+37.1%	$309.6M+64.1%	$188.6M+37.9%	$136.8M+23.2%	$111.0M+18.1%	$94.0M+74.9%	$53.7M
Current Assets	$644.2M-6.1%	$686.1M+39.1%	$493.1M-32.8%	$734.2M+22.0%	$601.6M-4.6%	$630.4M+33.4%	$472.6M-4.2%	$493.5M+116.0%	$228.5M+50.9%	$151.4M+42.9%	$105.9M-2.6%	$108.7M+11.9%	$97.2M+6.2%	$91.5M+85.1%	$49.4M
Cash & Equivalents	$128.4M+85.3%	$69.3M-7.6%	$75.1M-19.4%	$93.1M-54.2%	$203.4M-29.5%	$288.6M+59.1%	$181.4M-5.7%	$192.2M+91.7%	$100.3M+51.1%	$66.4M+98.2%	$33.5M-8.0%	$36.4M+10.4%	$33.0M-18.2%	$40.3M-17.0%	$48.5M
Short-Term Investments	$180.2M-53.1%	$384.3M+113.7%	$179.8M-51.2%	$368.2M+170.3%	$136.2M+1.8%	$133.9M-19.2%	$165.7M+1.2%	$163.8M+312.1%	$39.7M+67.5%	$23.7M-17.3%	$28.7M-24.4%	$37.9M-22.9%	$49.2M+2.1%	$48.2M	$0
Inventory	$112.5M+107.2%	$54.3M-29.9%	$77.4M-15.4%	$91.5M+6.5%	$86.0M+77.9%	$48.3M+81.5%	$26.6M+3.8%	$25.7M+57.4%	$16.3M-3.0%	$16.8M+33.5%	$12.6M-6.4%	$13.4M+87.9%	$7.2M+520.8%	$1.2M	N/A
Accounts Receivable	$187.8M+32.2%	$142.1M-1.4%	$144.2M-12.9%	$165.5M+11.1%	$148.9M+5.7%	$140.9M+61.3%	$87.3M-15.1%	$102.9M+56.9%	$65.6M+57.9%	$41.5M+60.3%	$25.9M+50.0%	$17.3M+241.7%	$5.1M+45845.5%	$11K-91.4%	$128K
Long-Term Investments	$0	$0-100.0%	$16.6M-82.3%	$93.9M-21.2%	$119.2M-66.0%	$350.4M-40.8%	$591.8M+41.3%	$418.8M+213.4%	$133.6M+77.2%	$75.4M+37.1%	$55.0M+177.6%	$19.8M+126.3%	$8.8M	$0	$0
Goodwill	$124.9M+6.7%	$117.0M0.0%	$117.0M0.0%	$117.0M-0.4%	$117.5M+50.8%	$77.9M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$390.9M+17.6%	$332.3M-6.7%	$356.2M-56.4%	$816.3M-6.5%	$873.3M+15.0%	$759.2M+34.4%	$564.9M+7.6%	$524.8M+234.3%	$157.0M+33.2%	$117.8M+17.1%	$100.6M+4.7%	$96.1M+23.9%	$77.5M+112.9%	$36.4M-17.8%	$44.3M
Current Liabilities	$338.2M+15.7%	$292.4M+0.8%	$290.2M-57.8%	$688.0M+118.1%	$315.4M+28.7%	$245.1M+52.6%	$160.6M-0.5%	$161.4M+31.2%	$123.0M+52.3%	$80.7M+41.8%	$56.9M+102.4%	$28.1M+6.5%	$26.4M+14.9%	$23.0M+22.4%	$18.8M
Non-Current Liabilities	$52.8M+32.1%	$39.9M-39.4%	$66.0M-48.6%	$128.3M-77.0%	$557.9M+8.5%	$514.1M+27.2%	$404.3M+11.2%	$363.4M+969.4%	$34.0M-8.3%	$37.1M-15.1%	$43.7M-35.7%	$68.0M+32.9%	$51.1M+280.6%	$13.4M-47.3%	$25.5M
Long-Term Debt	N/A	N/A	N/A	N/A	$379.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$23.2M	N/A
Total Equity	$1.1B+2.5%	$1.0B+12.4%	$921.5M+4.0%	$886.2M+8.6%	$815.9M+9.5%	$744.9M+25.1%	$595.4M+31.4%	$453.0M+69.4%	$267.5M+39.5%	$191.8M+117.9%	$88.0M+116.2%	$40.7M+21.6%	$33.5M-41.9%	$57.6M+509.7%	$9.4M
Retained Earnings	$517.9M-6.9%	$556.4M+15.3%	$482.6M+0.3%	$481.2M+26.7%	$379.9M+16.4%	$326.5M+63.6%	$199.5M+130.7%	$86.5M+422.5%	-$26.8M+68.2%	-$84.3M+52.0%	-$175.5M+7.4%	-$189.5M-6.1%	-$178.5M-107.0%	-$86.3M-115.8%	-$40.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.4B+3.3%	$1.5B+11.4%	$1.5B+6.2%	$1.4B+5.7%	$1.4B+5.1%	$1.3B+3.3%	$1.4B+7.1%	$1.3B+4.5%
Current Assets	$723.5M-2.1%	$731.6M+6.4%	$644.2M-6.1%	$593.9M-7.2%	$738.9M+25.0%	$687.6M+26.3%	$686.1M+39.1%	$640.0M+42.4%
Cash & Equivalents	$180.0M+24.4%	$184.9M+59.6%	$128.4M+85.3%	$151.4M+377.9%	$144.7M+177.8%	$115.8M+82.7%	$69.3M-7.6%	$31.7M-66.7%
Short-Term Investments	$192.1M-49.2%	$199.4M-42.7%	$180.2M-53.1%	$129.8M-65.1%	$377.9M+28.1%	$347.7M+48.4%	$384.3M+113.7%	$371.5M+253.2%
Inventory	$107.0M+143.1%	$110.8M+124.1%	$112.5M+107.2%	$107.1M+67.4%	$44.0M-35.4%	$49.4M-34.2%	$54.3M-29.9%	$64.0M-23.4%
Accounts Receivable	$211.7M+50.3%	$182.2M+25.1%	$187.8M+32.2%	$171.3M+17.8%	$140.8M-7.6%	$145.6M-1.4%	$142.1M-1.4%	$145.4M+2.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Goodwill	$119.4M+2.1%	$120.7M+3.1%	$124.9M+6.7%	$119.1M+1.8%	$117.0M0.0%	$117.0M0.0%	$117.0M0.0%	$117.0M0.0%
Total Liabilities	$396.9M+24.6%	$423.9M+33.9%	$390.9M+17.6%	$370.1M+10.3%	$318.5M-11.1%	$316.6M-15.6%	$332.3M-6.7%	$335.6M-10.0%
Current Liabilities	$347.4M+21.3%	$373.9M+32.7%	$338.2M+15.7%	$330.6M+13.4%	$286.4M-7.2%	$281.8M-10.4%	$292.4M+0.8%	$291.5M+1.4%
Non-Current Liabilities	$49.5M+54.0%	$50.0M+43.6%	$52.8M+32.1%	$39.5M-10.4%	$32.1M-35.3%	$34.8M-42.3%	$39.9M-39.4%	$44.0M-48.4%
Total Equity	$1.0B-3.1%	$1.1B+4.5%	$1.1B+2.5%	$1.0B+4.2%	$1.1B+11.1%	$1.0B+10.9%	$1.0B+12.4%	$1.0B+10.4%
Retained Earnings	$457.2M-19.4%	$515.6M-5.3%	$517.9M-6.9%	$522.0M-3.5%	$567.1M+12.8%	$544.6M+12.8%	$556.4M+15.3%	$541.1M+12.4%

Not reported in any period shown, so not listed: Long-Term Debt.

SUPN Cash Flow Statement

SUPN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$19.9M	$47.3M-72.5%	$172.0M+54.8%	$111.1M-4.9%	$116.8M-8.1%	$127.1M-8.1%	$138.4M-3.3%	$143.1M+11.0%	$129.0M+12.5%	$114.6M+71.6%	$66.8M+93.5%	$34.5M+240.9%	-$24.5M+57.7%	-$57.9M-22.8%	-$47.2M-30.4%	-$36.2M
Depreciation & Amortization	N/A	$91.6M+13.9%	$80.4M-5.2%	$84.9M-0.8%	$85.5M+162.4%	$32.6M+79.7%	$18.1M+172.4%	$6.7M-5.7%	$7.1M-13.1%	$8.1M+239.0%	$2.4M+160.5%	$921K-0.8%	$928K+25.1%	$742K-14.8%	$871K-0.9%	$879K
Stock-Based Compensation	N/A	$33.1M+19.1%	$27.8M+3.7%	$26.8M+52.3%	$17.6M-1.9%	$17.9M+8.1%	$16.6M+11.6%	$14.8M+31.5%	$11.3M+33.9%	$8.4M+42.3%	$5.9M+44.9%	$4.1M+43.2%	$2.9M+49.3%	$1.9M+331.8%	$443K+640.2%	-$82K
Capital Expenditures	$1.1M	$1.3M+84.6%	$725K+31.6%	$551K+33.7%	$412K	N/A	$3.4M+26.1%	$2.7M+224.2%	$844K-58.4%	$2.0M+26.6%	$1.6M-23.8%	$2.1M+254.8%	$593K-64.0%	$1.6M+118.6%	$753K+9.9%	$685K
Free Cash Flow	$18.8M	$46.0M-73.1%	$171.2M+54.9%	$110.5M-5.1%	$116.4M	N/A	$134.9M-3.9%	$140.4M+9.6%	$128.1M+13.8%	$112.6M+72.7%	$65.2M+101.1%	$32.4M+229.2%	-$25.1M+57.9%	-$59.6M-24.3%	-$48.0M-30.1%	-$36.9M
Investing Cash Flow	-$14.7M	$4.1M+102.2%	-$189.9M-170.7%	$268.7M+224.0%	-$216.7M-164.5%	-$81.9M-136.1%	-$34.7M+78.0%	-$157.9M+61.8%	-$413.5M-378.5%	-$86.4M-140.3%	-$36.0M+8.5%	-$39.3M-1377.6%	-$2.7M+78.0%	-$12.1M+75.3%	-$49.0M-244.4%	$33.9M
Financing Cash Flow	$31.5M	$9.1M-25.1%	$12.2M+103.1%	-$397.9M-3697.7%	-$10.5M+92.0%	-$130.4M-3764.5%	$3.6M-9.4%	$3.9M-99.0%	$376.4M+6526.3%	$5.7M+176.9%	$2.1M+9.9%	$1.9M-93.9%	$30.6M-51.3%	$62.7M-28.6%	$87.9M+224.6%	$27.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$4.8M-108.2%	$66.5M+117.4%	$19.9M-55.3%	-$61.7M-215.2%	$58.5M+64.3%	$30.6M-20.3%	$44.4M-1.2%	$53.5M+49.2%
Depreciation & Amortization	$400K-20.0%	$26.1M+28.2%	$25.0M+32.7%	$500K-16.7%	$500K-16.7%	$20.4M-1.8%	$18.8M-13.1%	$600K0.0%
Stock-Based Compensation	$8.6M+15.1%	$8.5M+5.1%	N/A	$30.7M+300.6%	$7.5M+14.6%	$8.1M+36.8%	N/A	$7.7M-3.1%
Capital Expenditures	$568K+24.8%	$0-100.0%	$427K+100.5%	$129K-35.5%	$455K+610.9%	$327K+31.9%	$213K+491.7%	$200K+33.3%
Free Cash Flow	-$5.4M-109.3%	$66.5M+119.8%	$19.4M-56.0%	-$61.8M-215.9%	$58.1M+63.3%	$30.3M-20.7%	$44.2M-1.6%	$53.3M+49.3%
Investing Cash Flow	$7.1M+123.2%	-$19.2M-151.5%	-$51.3M-306.0%	$48.7M+163.2%	-$30.6M+37.0%	$37.3M+172.3%	-$12.6M+80.8%	-$77.0M-322.4%
Financing Cash Flow	-$7.2M-870.1%	$9.1M+142.6%	$8.5M+44.8%	$21.1M+585.1%	$935K-43.6%	-$21.4M-1463.0%	$5.9M+439.4%	$3.1M+1437.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SUPN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SUPN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	89.6%+1.4pp	88.2%+2.0pp	86.2%-0.7pp	86.9%-0.1pp	87.1%-2.9pp	89.9%-5.8pp	95.8%-0.5pp	96.2%+1.3pp	95.0%+0.5pp	94.4%+0.1pp	94.3%+0.5pp	93.8%+3.0pp	90.8%	N/A	N/A
Operating Margin	-8.7%-21.0pp	12.3%+13.2pp	-0.9%-7.8pp	6.9%-7.9pp	14.8%-18.5pp	33.4%-4.5pp	37.8%+2.5pp	35.3%+2.4pp	32.9%+7.7pp	25.2%+11.1pp	14.1%+19.8pp	-5.7%	-515.2%	-2849.3%	-4701.4%
Net Margin	-5.4%-16.5pp	11.2%+11.0pp	0.2%-8.9pp	9.1%-0.1pp	9.2%-15.2pp	24.4%-4.4pp	28.8%+1.7pp	27.1%+8.2pp	18.9%-23.5pp	42.4%+33.0pp	9.5%+21.3pp	-11.8%	-767.7%	-3127.3%	6701.7%
Return on Equity	-3.6%-10.8pp	7.1%+7.0pp	0.1%-6.7pp	6.9%+0.3pp	6.6%-10.5pp	17.0%-2.0pp	19.0%-5.5pp	24.5%+3.1pp	21.4%-26.2pp	47.6%+31.7pp	15.8%+42.7pp	-26.8%+248.9pp	-275.7%-195.3pp	-80.4%-650.3pp	569.9%
Return on Assets	-2.7%-8.1pp	5.4%+5.3pp	0.1%-3.5pp	3.6%+0.4pp	3.2%-5.3pp	8.4%-1.3pp	9.7%-1.6pp	11.3%-2.2pp	13.5%-16.0pp	29.5%+22.1pp	7.4%+15.4pp	-8.0%+75.1pp	-83.1%-33.9pp	-49.2%-149.4pp	100.2%
Current Ratio	1.90-0.4x	2.35+0.6x	1.70+0.6x	1.07-0.8x	1.91-0.7x	2.57-0.4x	2.94-0.1x	3.06+1.2x	1.860.0x	1.880.0x	1.86-2.0x	3.87+0.2x	3.68-0.3x	3.98+1.3x	2.63
Debt-to-Equity	0.370.0x	0.32-0.1x	0.39-0.5x	0.92+0.5x	0.46-0.6x	1.02+0.1x	0.95-0.2x	1.16+0.6x	0.590.0x	0.61-0.5x	1.14-1.2x	2.360.0x	2.32+1.9x	0.40-4.3x	4.69
Asset Turnover	0.490.0x	0.480.0x	0.48+0.1x	0.390.0x	0.340.0x	0.350.0x	0.34-0.1x	0.42-0.3x	0.710.0x	0.69-0.1x	0.78+0.1x	0.68+0.6x	0.11+0.1x	0.020.0x	0.01
FCF Margin	6.4%-19.5pp	25.9%+7.7pp	18.2%+0.7pp	17.4%	N/A	25.9%-9.8pp	35.8%+4.4pp	31.3%-5.9pp	37.3%+6.9pp	30.3%+8.4pp	22.0%+49.0pp	-27.1%	-495.8%	-3240.0%	-4591.5%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	84.6%-5.2pp	88.7%-0.7pp	89.1%+4.1pp	90.1%+0.1pp	89.8%+0.5pp	89.5%+0.8pp	85.0%-3.1pp	90.0%+2.7pp
Operating Margin	-26.5%-33.8pp	-4.0%+2.8pp	-1.9%-14.1pp	-31.4%-54.6pp	7.3%-6.1pp	-6.9%-4.7pp	12.3%+12.9pp	23.3%+18.0pp
Net Margin	-26.7%-40.3pp	-1.1%+6.8pp	-2.0%-10.8pp	-23.5%-45.4pp	13.6%+1.8pp	-7.9%-8.0pp	8.8%+8.1pp	21.9%+32.3pp
Return on Equity	-5.7%-7.8pp	-0.2%+0.9pp	-0.4%-1.9pp	-4.3%-8.1pp	2.1%0.0pp	-1.1%-1.2pp	1.5%+1.4pp	3.8%+5.6pp
Return on Assets	-4.1%-5.7pp	-0.1%+0.7pp	-0.3%-1.4pp	-3.2%-6.0pp	1.6%+0.1pp	-0.9%-0.9pp	1.1%+1.0pp	2.9%+4.1pp
Current Ratio	2.08-0.5x	1.96-0.5x	1.90-0.4x	1.80-0.4x	2.58+0.7x	2.44+0.7x	2.35+0.6x	2.20+0.6x
Debt-to-Equity	0.38+0.1x	0.39+0.1x	0.370.0x	0.350.0x	0.30-0.1x	0.31-0.1x	0.32-0.1x	0.33-0.1x
Asset Turnover	0.150.0x	0.140.0x	0.150.0x	0.140.0x	0.120.0x	0.110.0x	0.130.0x	0.130.0x
FCF Margin	-2.5%-37.6pp	32.0%+11.8pp	9.2%-16.2pp	-32.2%-62.5pp	35.1%+14.0pp	20.2%-6.3pp	25.4%-2.0pp	30.3%+7.1pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Supernus Pharmaceuticals, Inc. SUPN	FY2025	$719.0M	-$38.6M	-5.4%	$2.5B	53/100
Alvotech ALVO	FY2025	$586.3M	$27.9M	4.8%	$2.1B	26/100
Indivior Pharmaceuticals, Inc. INDV	FY2025	$1.2B	$210.0M	17.0%	$4.2B	44/100
Kiniksa Pharmaceuticals International, plc KNSA	FY2025	$677.6M	$59.0M	8.7%	$6.2B	64/100
Bausch Health Companies Inc BHC	FY2025	$10.3B	$157.0M	1.5%	$2.3B	51/100
HUTCHMED (China) Limited HCM	FY2025	$548.5M	$456.9M	83.3%	$2.5B	42/100

Where Supernus Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Supernus Pharmaceuticals, Inc.'s annual revenue?

Supernus Pharmaceuticals, Inc. (SUPN) reported $719.0M in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Supernus Pharmaceuticals, Inc.'s revenue growing?

Supernus Pharmaceuticals, Inc. (SUPN) revenue grew by 8.6% year-over-year, from $661.8M to $719.0M in fiscal year 2025.

Is Supernus Pharmaceuticals, Inc. profitable?

No, Supernus Pharmaceuticals, Inc. (SUPN) reported a net income of -$38.6M in fiscal year 2025, with a net profit margin of -5.4%.

What is Supernus Pharmaceuticals, Inc.'s EBITDA?

Supernus Pharmaceuticals, Inc. (SUPN) had EBITDA of $29.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Supernus Pharmaceuticals, Inc.'s gross margin?

Supernus Pharmaceuticals, Inc. (SUPN) had a gross margin of 89.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Supernus Pharmaceuticals, Inc.'s operating margin?

Supernus Pharmaceuticals, Inc. (SUPN) had an operating margin of -8.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Supernus Pharmaceuticals, Inc.'s net profit margin?

Supernus Pharmaceuticals, Inc. (SUPN) had a net profit margin of -5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Supernus Pharmaceuticals, Inc.'s return on equity (ROE)?

Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity of -3.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Supernus Pharmaceuticals, Inc.'s free cash flow?

Supernus Pharmaceuticals, Inc. (SUPN) generated $46.0M in free cash flow during fiscal year 2025. This represents a -73.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Supernus Pharmaceuticals, Inc.'s operating cash flow?

Supernus Pharmaceuticals, Inc. (SUPN) generated $47.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Supernus Pharmaceuticals, Inc.'s total assets?

Supernus Pharmaceuticals, Inc. (SUPN) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Supernus Pharmaceuticals, Inc.'s capital expenditures?

Supernus Pharmaceuticals, Inc. (SUPN) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Supernus Pharmaceuticals, Inc. spend on research and development?

Supernus Pharmaceuticals, Inc. (SUPN) invested $106.2M in research and development during fiscal year 2025.

How many shares does Supernus Pharmaceuticals, Inc. have outstanding?

Supernus Pharmaceuticals, Inc. (SUPN) had 58M shares outstanding as of fiscal year 2025.

What is Supernus Pharmaceuticals, Inc.'s current ratio?

Supernus Pharmaceuticals, Inc. (SUPN) had a current ratio of 1.90 as of fiscal year 2025, which is generally considered healthy.

What is Supernus Pharmaceuticals, Inc.'s debt-to-equity ratio?

Supernus Pharmaceuticals, Inc. (SUPN) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Supernus Pharmaceuticals, Inc.'s return on assets (ROA)?

Supernus Pharmaceuticals, Inc. (SUPN) had a return on assets of -2.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Supernus Pharmaceuticals, Inc.'s P/E ratio?

Supernus Pharmaceuticals, Inc. (SUPN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Supernus Pharmaceuticals, Inc.'s price-to-sales ratio?

Supernus Pharmaceuticals, Inc. (SUPN) trades at 3.0x sales, its market capitalization divided by revenue of $830.4M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.5B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Supernus Pharmaceuticals, Inc.'s Altman Z-Score?

Supernus Pharmaceuticals, Inc. (SUPN) has an Altman Z-Score of 4.92, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Supernus Pharmaceuticals, Inc.'s Piotroski F-Score?

Supernus Pharmaceuticals, Inc. (SUPN) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Supernus Pharmaceuticals, Inc.'s earnings high quality?

Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $38.6M while generating $47.3M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Supernus Pharmaceuticals, Inc.?

Supernus Pharmaceuticals, Inc. (SUPN) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.